We’re thrilled to share that we're expanding our licensing agreement with Quanterix to advance next generation Alzheimer's disease biomarker research.
🔗Read the full announcement: alzpath.bio/alzpath-and-...
@alzpath.bsky.social
@alzpath.bsky.socialWe’re thrilled to share that we're expanding our licensing agreement with Quanterix to advance next generation Alzheimer's disease biomarker research.
🔗Read the full announcement: alzpath.bio/alzpath-and-...
@rcatanho.bsky.socialEn adultos mayores sin deterioro cognitivo, los niveles plasmáticos elevados de p-tau217 se asocian con un riesgo elevado de progresión clínica y deterioro cognitivo acelerado #ptau217 #cognitive #impairment jamanetwork.com/journals/jam...
@maraaspinall.bsky.socialIN THIS ISSUE
Finding #liverdisease hiding in plain sight
For people with cognitive deficits, most #pTau217 tests “work”
#AI that works in one species might not transfer to another
@jama.com📌 Editor’s Choice from this week's issue of JAMA:
➡️ #Plasma #pTau217 Levels and Future #Cognitive Decline,
➡️ Autonomous #AI vs AI-Aided #Physicians,
➡️ High-Dose IV #VitaminC and #SevereBurn Outcomes, and more.
